Subtopic Deep Dive

Phenothiazine Neuroprotective Effects
Research Guide

What is Phenothiazine Neuroprotective Effects?

Phenothiazine neuroprotective effects refer to the protective actions of phenothiazine derivatives, such as methylene blue, against neuronal damage from ischemia, neurodegeneration, and dopamine toxicity through antioxidant and anti-inflammatory mechanisms.

Research demonstrates methylene blue's neuroprotection in animal models of stroke and neurodegeneration (Poteet et al., 2012, 146 citations). Phenothiazines like prochlorperazine induce parkinsonian symptoms but also reveal receptor interactions relevant to neuroprotection (Christian and Paulson, 1958, 38 citations). Over 10 papers from 1958-2017 explore these dual effects in clinical and preclinical settings.

15
Curated Papers
3
Key Challenges

Why It Matters

Phenothiazine neuroprotection offers therapeutic potential for stroke and Parkinson's disease, as methylene blue reduces ischemic brain injury in rodent models (Poteet et al., 2012). Clinical observations of phenothiazine-induced dyskinesia highlight dopamine receptor modulation that could inform neuroprotective strategies (Godwin-Austen and Clark, 1971; Singer and Cheng, 1971). These properties support drug repurposing for neurodegeneration, balancing risks like parkinsonism (Myrianthopoulos et al., 1962).

Key Research Challenges

Balancing Dyskinesia Risks

Phenothiazines cause persistent dyskinesia and parkinsonism, complicating neuroprotective use (Godwin-Austen and Clark, 1971, 53 citations; Myrianthopoulos et al., 1962, 55 citations). Studies show treatments like tetrabenazine mitigate symptoms but do not eliminate underlying dopamine toxicity risks. Developing safer derivatives remains critical.

Translating Animal Models

Methylene blue shows neuroprotection in ischemia models, but human trials lack (Poteet et al., 2012, 146 citations). Receptor pharmacology differences between species hinder extrapolation. Clinical side effects like motility disturbances underscore translation gaps (Christian and Paulson, 1958).

Optimizing Pharmacokinetics

Lipophilicity and ADMET properties affect brain penetration for neuroprotection (Klimoszek et al., 2024, 42 citations). Phenothiazine derivatives vary in crossing blood-brain barrier. Balancing efficacy with toxicity requires precise structure-activity tuning.

Essential Papers

1.

Neuroprotective Actions of Methylene Blue and Its Derivatives

Ethan Poteet, Ali Winters, Liang‐Jun Yan et al. · 2012 · PLoS ONE · 146 citations

Methylene blue (MB), the first lead chemical structure of phenothiazine and other derivatives, is commonly used in diagnostic procedures and as a treatment for methemoglobinemia. We have previously...

2.

Possible Biological and Clinical Applications of Phenothiazines

Borisz Varga, Ákos Csonka, Andrea Csonka et al. · 2017 · Anticancer Research · 135 citations

Phenothiazines have been used in many areas of medicine, mainly in psychopharmacology. These compounds are able to effectively inhibit dopamine, histamine, serotonin, acetylcholine, and α-adrenergi...

3.

A Review: Medicinally Important Nitrogen Sulphur Containing Heterocycles

Praveen Kumar Sharma, Andleeb Amin, Manjeet Kumar · 2020 · The Open Medicinal Chemistry Journal · 75 citations

Nitrogen sulphur containing heterocycles have specific properties due to which they can be used as a potential material in a different type of industries such as medicinal/pharmaceutical, paint, pa...

4.

Hereditary Predisposition in Drug-Induced Parkinsonism

Ntinos C. Myrianthopoulos, A. A. Kurland, L. T. Kurland · 1962 · Archives of Neurology · 55 citations

One of the most striking side-effects of ataraxic drug therapy is the manifestation of parkinsonian symptoms of varying severity. Some clinicians are of the opinion that these symptoms, though simi...

5.

Persistent Phenothiazine Dyskinesia Treated with Tetrabenazine

R B Godwin-Austen, T. J. H. Clark · 1971 · BMJ · 53 citations

Six patients with persistent phenothiazine dyskinesia were treated in a double-blind controlled trial with tetrabenazine 100 mg in divided dosage. In three patients the abnormal movements were abol...

6.

Study of the Lipophilicity and ADMET Parameters of New Anticancer Diquinothiazines with Pharmacophore Substituents

Daria Klimoszek, Małgorzata Jeleń, Małgorzata Dołowy et al. · 2024 · Pharmaceuticals · 42 citations

Lipophilicity is one of the principal parameters that describe the pharmacokinetic behavior of a drug, including its absorption, distribution, metabolism, elimination, and toxicity. In this study, ...

7.

Sulfonamides: Synthesis and the recent applications in Medicinal Chemistry

Mohamed I. H. El‐Qaliei, M. S. A. El‐Gaby, Yousry A. Ammar et al. · 2020 · Egyptian Journal of Chemistry · 42 citations

This review spotlights sulfonamides from different sides, including history, structure-activity relationship, chemistry, methods of classification and up to date ways for their synthesis. Moreover,...

Reading Guide

Foundational Papers

Start with Poteet et al. (2012, 146 citations) for methylene blue mechanisms in ischemia; follow with Myrianthopoulos et al. (1962, 55 citations) and Godwin-Austen and Clark (1971, 53 citations) for clinical risks defining safe dosing.

Recent Advances

Study Varga et al. (2017, 135 citations) for clinical applications and Klimoszek et al. (2024, 42 citations) for ADMET optimization in neuroprotective derivatives.

Core Methods

Core techniques: rodent stroke models (Poteet et al., 2012), double-blind dyskinesia trials (Godwin-Austen and Clark, 1971), lipophilicity assays (Klimoszek et al., 2024).

How PapersFlow Helps You Research Phenothiazine Neuroprotective Effects

Discover & Search

Research Agent uses searchPapers and citationGraph to map 146-cited Poteet et al. (2012) connections, revealing clusters on methylene blue neuroprotection; exaSearch uncovers hidden clinical trials on phenothiazine dyskinesia; findSimilarPapers expands to Varga et al. (2017) for broader applications.

Analyze & Verify

Analysis Agent applies readPaperContent to extract antioxidant mechanisms from Poteet et al. (2012); verifyResponse with CoVe cross-checks claims against Myrianthopoulos et al. (1962); runPythonAnalysis computes citation trends and GRADE scores evidence from 1958-2024 papers for methodological rigor.

Synthesize & Write

Synthesis Agent detects gaps in human trial data between animal neuroprotection (Poteet et al., 2012) and dyskinesia risks (Godwin-Austen and Clark, 1971); Writing Agent uses latexEditText, latexSyncCitations, and latexCompile to draft reviews; exportMermaid visualizes receptor interaction pathways.

Use Cases

"Analyze dose-response of phenothiazines in ischemia models from Poteet 2012"

Analysis Agent → readPaperContent (Poteet et al.) → runPythonAnalysis (NumPy curve fitting on MB doses) → matplotlib dose-response plot with statistical p-values.

"Write LaTeX review on phenothiazine neuroprotection vs parkinsonism risks"

Synthesis Agent → gap detection (Poteet 2012 vs Myrianthopoulos 1962) → Writing Agent → latexEditText (structure review) → latexSyncCitations → latexCompile → PDF with diagrams.

"Find GitHub code for methylene blue simulation models"

Research Agent → paperExtractUrls (Poteet et al. supplements) → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis on simulation scripts for neuroprotection metrics.

Automated Workflows

Deep Research workflow scans 50+ phenothiazine papers via searchPapers → citationGraph → structured report on neuroprotection trends (Poteet et al., 2012). DeepScan applies 7-step CoVe to verify antioxidant claims against dyskinesia data (Godwin-Austen and Clark, 1971). Theorizer generates hypotheses on receptor-specific neuroprotection from Varga et al. (2017).

Frequently Asked Questions

What defines phenothiazine neuroprotective effects?

Phenothiazine neuroprotective effects are antioxidant and anti-inflammatory actions of derivatives like methylene blue against ischemia and neurodegeneration (Poteet et al., 2012).

What are key methods in this research?

Methods include animal ischemia models, receptor binding assays, and clinical observation of dopamine-related side effects (Poteet et al., 2012; Christian and Paulson, 1958).

What are the most cited papers?

Top papers are Poteet et al. (2012, 146 citations) on methylene blue neuroprotection and Myrianthopoulos et al. (1962, 55 citations) on drug-induced parkinsonism.

What open problems exist?

Challenges include translating animal neuroprotection to humans and mitigating dyskinesia risks (Godwin-Austen and Clark, 1971; Klimoszek et al., 2024).

Research Phenothiazines and Benzothiazines Synthesis and Activities with AI

PapersFlow provides specialized AI tools for Biochemistry, Genetics and Molecular Biology researchers. Here are the most relevant for this topic:

See how researchers in Life Sciences use PapersFlow

Field-specific workflows, example queries, and use cases.

Life Sciences Guide

Start Researching Phenothiazine Neuroprotective Effects with AI

Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.

See how PapersFlow works for Biochemistry, Genetics and Molecular Biology researchers